It is of interest that use of two antagonists together produced a reversal of enhanced mGluR-LTD in Cyfip1 heterozygous mice in our experiments, suggesting that a combined approach would be beneficial in both 15q11.2 CNV patients but also in FXS. This evidence concerns the gene CYFIP1 and fragile X syndrome.